Clinical Trial Update: TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer. [Phase 2]

View source ↗

Summary

Phase 2 trial update for TQB2450 plus paclitaxel and cisplatin with or without anlotinib in esophageal neoplasms (esophageal cancer).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Neoplasms

Drugs mentioned

• Anlotinib (anlotinib)
• CISPLATIN (cisplatin)
• PACLITAXEL (PACLITAXEL)
• TQB2450

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Esophageal Neoplasms | Phase 2 | Status: UNKNOWN